Pigmentary glaucoma is a type of glaucoma—an eye disorder that can lead to vision loss—that affects the iris, or colored part of the eye. This condition is caused by deposits of pigment in the front chamber of the eye, which is filled with fluid. When these deposits build up, they can block or reduce the flow of fluid within the eye, resulting in high levels of pressure inside it. If left untreated, pigmentary glaucoma can lead to permanent vision damage and even blindness.
Pigmentary glaucoma is a type of glaucoma that is caused by the buildup of pigment in the eye. This can cause the pressure in the eye to increase, which can damage the optic nerve and lead to vision loss. Pigmentary glaucoma is more common in people with darker skin, and it is often hereditary. Symptoms of pigmentary glaucoma include decreased vision, halos around lights, and headaches.
Pigmentary glaucoma is a relatively rare form of glaucoma that occurs when pigment particles from the iris build up in the drainage channels of the eye, causing blockage. This can lead to increased pressure within the eye, which can damage the optic nerve and lead to vision loss. There are two main types of pigmentary glaucoma: primary open-angle glaucoma (POAG) and angle-closure glaucoma (ACG).
POAG is the most common type of pigmentary glaucoma, accounting for about 70% of cases. It typically affects people over the age of 40 and tends to run in families. ACG is less common, but tends to be more severe, affecting people of all ages. In both types of disease, symptoms may include headaches, eye pain, halos around lights, and vision loss.
Pigmentary glaucoma is a relatively rare form of glaucoma that is caused by the build-up of pigment in the eye. While this condition can lead to vision problems, it is important to note that not all cases of pigmentary glaucoma are severe. In fact, many people with this condition experience only mild symptoms and never develop serious vision problems.
However, pigmentary glaucoma can be a serious condition if it is left untreated. This type of glaucoma can cause optic nerve damage and vision loss.
There are both pros and cons to having pigmentary glaucoma. Some of the pros include:
1. Pigmentary glaucoma is not as common as other types of glaucoma, so there is less information available about it.
2. Because pigmentary glaucoma is not as well-known, some insurance companies may be more likely to cover the cost of treatment than they would for other types of glaucoma.
3. There are typically few side effects associated
Alternatives to the Treatments for Pigmentary Glaucoma
While there is no cure for pigmentary glaucoma, there are treatments that can help to improve symptoms and slow the progression of the disease. These treatments include:
-Prescription eye drops: Eye drops can help to lower intraocular pressure (IOP), which can help to relieve symptoms and prevent further damage to the optic nerve.
-Laser surgery: Laser surgery can be used to improve drainage from the eye, which can help to lower IOP.
-Injections: Injections of medication into the eye can also help to lower IOP.
-Surgery: Surgery is sometimes necessary to improve drainage from the eye or to remove part of the iris (the colored part of the eye) if it is obstructing proper drainage.
In conclusion, identifying the signs and symptoms of pigmentary glaucoma is important in order to start treatment early.
1.
Imfinzi + Imjudo, EU approved for patients with advanced lung cancer and non-small cell lung cancer: AstraZeneca
2.
More Support for Early Detection; Cancer in Men Rising; Diet Drives Colon Cancer
3.
Asymptomatic Brain Metastases in EGFR-Mutant NSCLC
4.
Mapping lifelong chronic health risks for childhood cancer survivors
5.
Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC
1.
Respiratory Ramifications of Systemic Disease: A Comprehensive Review
2.
Revolutionizing Lung Cancer Treatment: Exploring the Benefits of Wedge Resection Surgery
3.
Trends in Incidence, Care, and Surgery for Medullary Thyroid Cancer: A Review
4.
Cancer Care Advances: Metformin, Digital Tools, and Artificial Renal Support
5.
Molecular Mechanisms, Clinical Efficacy, and Stem Cell Therapy Integration in Leukemia Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions
2.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
3.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation